Phase IB/II of CPX-351 as Maintenance Therapy in AML Patients Ineligible for Bone Marrow Transplantation
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Cytarabine/daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 03 Jul 2024 Planned End Date changed from 1 Aug 2024 to 1 Aug 2025.
- 03 Jul 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.
- 11 Sep 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.